The epidermal growth factor receptor as a target for therapy in breast carcinoma Journal Article

  


Authors: Baselga, J.; Mendelsohn, J.
Article Title: The epidermal growth factor receptor as a target for therapy in breast carcinoma
Abstract: The epidermal growth factor (EGF) receptor and its ligands have an important regulatory role in breast carcinoma. We have produced a series of monoclonal antibodies (MAbs) directed against the external portion of the EGF receptor. These MAbs prevent the binding of the ligands to the receptor, block ligand-induced activation of the receptor, and can inhibit the growth of breast cancer cells both in tissue culture and in human tumor xenografts in nude mice. We have also shown that anti-EGF receptor antibodies greatly enhance the antitumor effects of chemotherapeutic agents active in breast cancer. Phase I clinical trials with single doses of MAb conducted in patients with tumors over-expressing EGF receptors demonstrated favorable pharmacokinetics, good tumor imaging, and a lack of toxicity. A human:murine chimeric antibody has been produced with comparable affinity and antitumor activity that will enable us to administer repeated doses of MAb either alone or in combination with chemotherapy. Our pre-clinical data support the concept that the EGF receptor may be an optimal target for treatment with receptor blocking antibodies, either alone or in combination with chemotherapy. © 1994 Kluwer Academic Publishers.
Keywords: human cell; clinical trial; doxorubicin; nonhuman; chemotherapy; adenocarcinoma; mouse; animal; mice; cell division; cancer immunotherapy; epidermal growth factor receptor; animal experiment; animal model; receptor, epidermal growth factor; tumor xenograft; tumor cells, cultured; breast neoplasms; monoclonal antibodies; monoclonal antibody; cancer inhibition; antibodies, monoclonal; immunoglobulin g; nude mouse; breast carcinoma; transplantation, heterologous; imaging; phase 1 clinical trial; ligand binding; clinical trials; egf receptor; intraperitoneal drug administration; clinical trials, phase i; human; female; priority journal; article; support, non-u.s. gov't; support, u.s. gov't, p.h.s.; chimeric proteins; humanized antibodies
Journal Title: Breast Cancer Research and Treatment
Volume: 29
Issue: 1
ISSN: 0167-6806
Publisher: Springer  
Date Published: 1994-01-01
Start Page: 127
End Page: 138
Language: English
DOI: 10.1007/bf00666188
PUBMED: 8018961
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028268289&doi=10.1007%2fBF00666188&partnerID=40&md5=9af501d7799ac06c1988379c18431ba7
Notes: Editorial -- Export Date: 14 January 2019 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Jose T Baselga
    484 Baselga
  2. John Mendelsohn
    128 Mendelsohn
Related MSK Work